Abstract #0322
The tumor exception that proves the rule: Hyperpolarized 13 C MRS cannot be used to detect the presence of mutant IDH1 glioma or their responses to Temozolomide therapy
Myriam Marianne Chaumeil 1 , Marina Radoul 1 , Pia Eriksson 1 , Michael D Blough 2 , Charles Cheneslong 2 , Russell O Pieper 3,4 , Joanna J Phillips 3,4 , J Gregory Cairncross 2 , and Sabrina M Ronen 1,4
1
Radiology and Biomedical Imaging, University
of California San Francisco, San Francisco, CA, United
States,
2
Clinical
Neurosciences, University of Calgary, Calgary, Alberta,
Canada,
3
Neurological
Surgery, University of California San Francisco, San
Francisco, CA, United States,
4
Brain
Tumor Research Center, University of California San
Francisco, San Francisco, CA, United States
Recent studies show that
13
C
MRSI of hyperpolarized (HP) pyruvate can serve as an
indicator of response to Temozolomide in primary
glioblastoma. However, this imaging method had never
been applied to mutant IDH1 gliomas, in which LDH-A is
silenced. Here, we show that, in contrast to
glioblastoma, mutant IDH1 oligodendrogliomas or
oligoastrocytomas cells and tumors do not produce a
significant amount of HP lactate, making these tumors
virtually invisible by HP
13
C
MRSI. Furthermore, we demonstrate that TMZ treatment
does not affect HP lactate levels in oligodendrogliomas
or oligoastrocytomas, highlighting the need for new
biomarkers specific to these tumor types.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
